This study investigated the real-world clinical experience of a ROS1-rearranged NSCLC cohort on first exposure to a ROS1-inhibiting therapy, crizotinib, in Alberta, Canada. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.